AGRX

In a report released on November 8, Naz Rahman from Maxim Group maintained a Buy rating on Agile Therapeutics (AGRX - Research Report), with a price target of $1.00. The company's shares closed yesterday at $0.20.According to TipRanks, Rahman is an analyst with an average return of -38.3% and a 16.88% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Clene.Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $3.00.
https://www.tipranks.com/news/blurbs/agile-therapeutics-agrx-gets-a-buy-from-maxim-group?utm_source=advfn.com&utm_medium=referral